ARMS法与下一代测序法检测非小细胞肺癌EGFR基因突变的比较

A comparison of ARMS assay and next-generation sequencing performance in EGFR mutations analysis of non-small cell lung cancer patients

目的本研究旨在通过对突变扩增阻滞系统(ARMS)法与下一代测序法(NGS)检测非小细胞肺癌(NSCLC)EGFR基因突变的比较分析,来探索更适合我国临床肺癌患者EGFR基因突变的检测方法。方法收集22例NSCLC患者标本,分别用ARMS法及二代测序法对标本进行EGFR基因突变检测,分析比较两种方法的优劣。结果本次实验的22例标本其中17例EGFR基因突变结果两种检测方法一致,结果为EGFR单突变6例,双突变1例,阴性10例;2例ARMS法检测为单突变,二代测序法检测为双突变;3例ARMS法未检测到突变,二代测序法检测到突变。结论 ARMS法与二代测序法检测EGFR基因突变结果基本一致,但各有优缺点,两种方法结合检测效果更好。

Objective The purpose of this study is to compare the ARMS and Next-generation sequencing methods to detect EGFR mutations in non-small cell lung cancer, and to explore a more suitable method for the detection of gene mu- tations in Chinese patients with lung cancer. Methods Specimens of 22 patients with NSCLC were collected, then the EG- FR mutations were detected by ARMS and Next-generation sequencing. Finally, the advantages and disadvantages of the two methods are analyzed and compared. Results In the 22 specimens of this experiment, There were 7 cases detected the same EGFR mutation and 10 cases were detected EGFR wild-type by both methods, while 2 cases were detected double mu- tations by Next-generation sequencing, whereas the ARMS assay were single mutation, and 3 cases were detected nmtations by Next-generation sequencing, whereas the ARMS assay were not detected. Conclusion ARMS assay and Next-genera- tion sequencing exhibited similar efficacy in detecting EGFR mutations, But the two methods have their own advantages and disadvantages. Terefore, the combination of Next-generation sequencing and ARMS assay could provide more reliable and comprehensive test results than the lone application of each technique .